● Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Relapsed or Refractory Multiple Myeloma · Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

PhasePhase 1

Planned participants130

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.

This description comes directly from the study's public registry record.

Talk to the study team

Study Contact · 8573330740 · clinicaltrials@simceregroup.com

Wenjuan Wang · wangwenjuan4@simceregroup.com

Always discuss trial participation with your own doctor first.

Locations (11)

Mayo Clinic Arizona	Phoenix, Arizona, United States	Recruiting
Mayo Clinic Florida	Jacksonville, Florida, United States	Recruiting
Dana Farber Cancer institution	Boston, Massachusetts, United States	Not Yet Recruiting
Mayo Clinic Rochester	Rochester, Minnesota, United States	Recruiting
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health	New York, New York, United States	Recruiting
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute	New York, New York, United States	Recruiting
Beijing Chaoyang Hospital Capital Medical University	Beijing, Beijing Municipality, China	Recruiting
Sun Yat-sen University Cancer Center	Guangzhou, Guangdong, China	Recruiting
Henan Cancer Hospital	Zhengzhou, Henan, China	Recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences	Tianjin, Tianjin Municipality, China	Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine	Hanzhou, Zhejiang, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06375044